Research using Mesenchymal Stem/Stromal Cells: Quality metric towards developing a reference material

Cytotherapy

Volumn 17, Issue 9, 2015, Pages 1169-1177

  Tanavde, Vivek ^a,e   Vaz, Candida ^a   Rao, Mahendra S ^c   Vemuri, Mohan C ^b   Pochampally, Radhika R ^d  

^a BIOINFORMATICS INSTITUTE   (Singapore)

^b Thermo Fisher Scientific   (United States)

^c Q Thera   (United States)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXPANSION; CELL ISOLATION; CELL THERAPY; CLINICAL PROTOCOL; DISEASE MARKER; EPIGENETICS; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; WOUND HEALING; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL SEPARATION; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES; STANDARD; STANDARDS;

CELL CULTURE TECHNIQUES; CELL SEPARATION; CELLS, CULTURED; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; REFERENCE STANDARDS;

EID: 84945952039     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.07.008     Document Type: Review

References (45)

1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
2. Casaroli-Marano R.P., Tabera J., Vilarrodona A., Trias E. Regulatory issues in cell-based therapy for clinical purposes. Dev Ophthalmol 2014, 53:189-200.
3. Rosner M., Schipany K., Hengstschlager M. The decision on the "optimal" human pluripotent stem cell. Stem Cells Transl Med 2014, 3:553-559.
4. Reger R.L., Prockop D.J. Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells?. Stem Cells Transl Med 2014, 3:632-635.
5. Viswanathan S., Keating A., Deans R., Hematti P., Prockop D., Stroncek D.F., et al. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev 2014, 23:1157-1167.
6. Kucia M., Reca R., Campbell F.R., Zuba-Surma E., Majka M., Ratajczak J., et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006, 20(5):857-869.
7. Reyes M., Verfaillie C.M. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 2001, 938:231-233. discussion 233-5.
8. Lu L.L., Liu Y.J., Yang S.G., Zhao Q.J., Wang X., Gong W., et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006, 91:1017-1026.
9. Wang H.S., Hung S.C., Peng S.T., Huang C.C., Wei H.M., Guo Y.J., et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004, 22:1330-1337.
10. Bunnell B.A., Flaat M., Gagliardi C., Patel B., Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods 2008, 45:115-120.
11. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3:393-403.
12. Jones E., McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford) 2008, 47:126-131.
13. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012, 10:709-716.
14. Food and Drug Administration. Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products: Draft Guidance for Industry and Food and Drug Administration Staff. 2014; Available from:. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM427746.pdf.
15. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95:9-20.
16. Phinney D.G., Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 2005, 11:1255-1265.
17. Wang Y., He J., Pei X., Zhao W. Systematic review and meta-analysis of mesenchymal stem/stromal cells therapy for impaired renal function in small animal models. Nephrology (Carlton) 2013, 18:201-208.
18. Bernardo M.E., Pagliara D., Locatelli F. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine?. Bone Marrow Transplant 2012, 47:164-171.
19. Barzilay R., Melamed E., Offen D. Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. Stem Cells 2009, 27:2509-2515.
20. Phinney D.G., Prockop D.J. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007, 25:2896-2902.
21. Sasaki M., Abe R., Fujita Y., Ando S., Inokuma D., Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 2008, 180:2581-2587.
22. Evans C.H. Gene delivery to bone. Adv Drug Deliv Rev 2012, 64:1331-1340.
23. Pochampally R.R., Horwitz E.M., DiGirolamo C.M., Stokes D.S., Prockop D.J. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther 2005, 12:1119-1125.
24. Yi T., Song S.U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 2012, 35:213-221.
25. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
26. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008, 3:e1886.
27. Dittmer J., Leyh B. Paracrine effects of stem cells in wound healing and cancer progression (Review). Int J Oncol 2014, 44:1789-1798.
28. Lee J.W., Fang X., Krasnodembskaya A., Howard J.P., Matthay M.A. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011, 29:913-919.
29. Kupcova Skalnikova H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 2013, 95:2196-2211.
30. Penfornis P., Vallabhaneni K.C., Whitt J., Pochampally R. Extracellular vesicles as carriers of microRNA, proteins and lipids in tumor microenvironment. Int J Cancer 2015.
31. Vallabhaneni K.C., Penfornis P., Dhule S., Guillonneau F., Adams K.V., Mo Y.Y., et al. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins, and metabolites. Oncotarget 2015, 6:4953-4967.
32. Zhang J., Guan J., Niu X., Hu G., Guo S., Li Q., et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med 2015, 13:49.
33. Carpenter M.K., Rosler E., Rao M.S. Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 2003, 5:79-88.
34. Brown P.T., Squire M.W., Li W.J. Characterization and evaluation of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. Cell Tissue Res 2014, 358:149-164.
35. Li O., Tormin A., Sundberg B., Hyllner J., Le Blanc K., Scheding S. Human embryonic stem cell-derived mesenchymal stroma cells (hES-MSCs) engraft in vivo and support hematopoiesis without suppressing immune function: implications for off-the shelf ES-MSC therapies. PLoS One 2013, 8:e55319.
36. Jeong J., Shin K., Lee S.B., Lee D.R., Kwon H. Patient-tailored application for Duchene muscular dystrophy on mdx mice based induced mesenchymal stem cells. Exp Mol Pathol 2014, 97:253-258.
37. Chen Y.S., Pelekanos R.A., Ellis R.L., Horne R., Wolvetang E.J., Fisk N.M. Small molecule mesengenic induction of human induced pluripotent stem cells to generate mesenchymal stem/stromal cells. Stem Cells Transl Med 2012, 1:83-95.
38. Miao Q., Shim W., Tee N., Lim S.Y., Chung Y.Y., Ja K.P., et al. iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium. J Cell Mol Med 2014, 18:1644-1654.
39. Frobel J., Hemeda H., Lenz M., Abagnale G., Joussen S., Denecke B., et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Reports 2014, 3:414-422.
40. Sheyn, D.B.-D., Shiran; Ann De Mel, Sandra; Ornelas, Loren; Sahabian, Anais; Sareen, Dhruv et al. Ips Cells Can Be Efficiently Differentiated Back To MSCs Using Shorty Exposure To Tgf? in Orthopaedic Research Society 2015 Annual Meeting. 2015. Las Vegas, Nevada.
41. Junker B.H. Flux analysis in plant metabolic networks: increasing throughput and coverage. Curr Opin Biotechnol 2014, 26:183-188.
42. James S., Fox J., Afsari F., Lee J., Clough S., Knight C., et al. Multiparameter Analysis of Human Bone Marrow Stromal Cells Identifies Distinct Immunomodulatory and Differentiation-Competent Subtypes. Stem Cell Reports 2015, 4:1004-1015.
43. Barata J.T., Cardoso A.A., Nadler L.M., Boussiotis V.A. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 2001, 98:1524-1531.
44. Sexl V., Piekorz R., Moriggl R., Rohrer J., Brown M.P., Bunting K.D., et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood 2000, 96:2277-2283.
45. Al-Rawi M.A., Rmali K., Watkins G., Mansel R.E., Jiang W.G. Aberrant expression of interleukin-7 (IL-7) and its signalling complex in human breast cancer. Eur J Cancer 2004, 40:494-502.